Member Info for Basser1

Sareum (Garry Kane) on only his second day of Registration on Stocktwits has another post today quote

Nick Glover bet on the wrong horse. SRA 737 is where the value is, not Momelotinib.
GILEAD only came on board for SRA 737, trust me. Time will prove me right.

Intriguing. Who is this guy?

I think it was around 1.9p but I have had plenty of time to average down. Hope you have to.

Nice one Aber - I have been here much longer than Parker - 2010!

I agree. With the massive interest in TYH2 don’t think we will have to wait too long
Cheers GLA

Thanks Bighow. See we are in the Top 8 Pharmas again for TYK2

As Warren Buffet would say’ The Stockmarket is a device for transferring money from the impatient to the patient.’
The Science is on our side

Be careful, With all this attention his ears may be burning and he might make a comeback. Lol

Thanks Zylo

Krone - can you take a look at the latest post under the name of ‘Sareum’ which states the only reason that is driving the Sierra rise in price is SRA 737 and encourages people to look at the Sareum website. Has this post originated from Sareum or have I got confused???

Yes, another nice and steady rise for Sareum. Even Sierra looks like it might be waking up from its slumber. Congratulations to this bulletin Board for some great research findings and in the main, constructive comments. I do think that Bighow’s find on the market research of TYK2 was a great boost for us as it demonstrates that we are in the big league with the well established Pharmas and enhances the company’ status. I think We need to be careful about overhyping the opportunity re Covd19. Yes we have the potentially
Best in Class TYK2 in SDC-01 and we are in the competition but it’s important that we continue to focus just as much if not more, on the massive potential of SDC-01 and SDC-02 in the treatment of a range of Cancers and Inflammatory conditions. These are the company’s Crown Jewels and if successful the financial returns on these will be truly eye watering. We are more than a one trick pony. GLA

Very relaxed - get these out of the way and we will move up again quickly.

What’s going on - we are now showing 16 percent up with a rediculous Spread of 0.80-0.90

Thats wrong Steve. We have very good cover from the granting of the earlier US patent.

Nice steady start to the week. Investors at last seeing that the Scientific research is on our side.

Yes we are in the list of the Top manufactures for TYK2. Look at their market Capital
Array. 10.68Billion
Bristol Myers137 Billion
Pfizer 204 Billion
Portola 500 Million
Takeda 53 Billion
Theravance 1.68 Billion
We have two TYK 2 Molecules for Cancer and Autoimmune which are potentially best in class. As well as Aurora and Sar737 and our market cap- 24 Million. Lol.
What a bargain buy. DYOR

Sierra’s Momelotinib, currently in Phase 3 trials is expecting revenues of 3 BillionDollars a year for the treatment of myelofibrosis. Our products have potential to cover a wide range of Cancers and inflammatory diseases. Think about it

Let’s hope Tim, John and Stephen are doing the rounds of the big Parma’s extolling the virtues of SDC1801, especially its low toxicity. Fingers crossed

Great article Krone. Clearly demonstrates that at the moment the priority is to address the over reaction of the immune system to Covid19 that can result in the release of Cytokines storms leading to organ damage Sepsis and death. Sareum’s SDC-01 is exactly the type of molecule to dampen down the immune systems overreaction and give the body time to fight off the infection. What’s more the current SDC-01 Toxicity tests are showing low toxicity responses. As we have seen in an earlier post on the Board some of the warnings on more established drugs in this field are quite frightening. I would have thought that the low Toxicity of SDc-01 would be one of the major criteria to be considered for any candidate selection. We will soon find out.

Hey Lads - we’ve Just had a great week with the Share price more than doubling. Let’s not speculate on a placing when the company has stated that they have enough funding till at least the end of the year. We have another big week coming up and we need to go into it on a positive note.

Great to hear from you wanderers. Let’s here from all you silent individual shareholders
Your views are welcomed and add value to the debate